Jonathan Mwiindi Thuranira
ID:
|
EMERGENCY CESAREAN SECTION AND LENGTH OF STAY IN HOSPITALS IN UGANDA
REFNo: HS1093ES
1. To determine if payer-type (SAFE vs. self-pay) is associated with the decision to delivery interval (DDI) for rural Uganda women undergoing an emergency C-section in Nyakibale Hospital and Rushoroza Hospital. The DDI is the first phase of the aggregated LOS.
2. To determine if payer-type (SAFE vs. self-pay) is associated with the aggregate LOS for rural Uganda women undergoing an emergency C-section in Nyakibale Hospital and Rushoroza Hospital in rural Uganda while adjusting for the Decision to Delivery Interval (DDI).
3. To describe the experience of eight young mothers (aged 18-25) having their second (or more) C-Section delivered by emergency C-section in Southwest Uganda under the SAFE program during April 2020.
|
Kenya |
2021-02-08 |
2024-02-08 |
Medical and Health Sciences |
|
Degree Award |
|
Bonaventure Ssebyanzi Wasswa
ID:
|
PRIMARY SCHOOL SUPPORT SYSTEMS TO DEAF CHILDREN LEADING TO THEIR TRANSITION TO POST-PRIMARY EDUCATION IN UGANDA
REFNo: SS590ES
(i) To investigate the support systems for deaf children at the completion of primary school studies.
(ii) To examine the situation of deaf children at the completion of primary studies.
(iii) To explore the self of deaf children at the completion of primary studies.
(iv) To establish the strategies for transition to post-primary level of deaf children at the completion of primary studies.
|
Uganda |
2021-02-05 |
2024-02-05 |
Social Science and Humanities |
|
Degree Award |
|
Alex Taremwa Taremwa
ID: UNCST-2020-R014302
|
VIABILITY OF DIGITAL SUBSCRIPTION IN EAST AFRICA – AN ANALYSIS OF VIUSASA AND CHIMPREPORTS’ PAYWALLS
REFNo: SS629ES
1. To identify critical success factors for subscription-based models in digital media platforms.
2. To establish the barriers to subscription uptake among digital media in East Africa.
3. To assess the critical success factors against the ChimpReports and Viusasa’s strategies.
4. To analyse the consumption habits of audiences in line with payment for digital content on Viusasa and Chimp.
|
Uganda |
2021-02-05 |
2024-02-05 |
Social Science and Humanities |
|
Degree Award |
|
Joseph Lutaakome
ID: UNCST-2020-R008323
|
An open-label, roll-over study with rilpivirine in combination with a background regimen containing other antiretrovirals (ARVs) in human immunodeficiency virus type 1 (HIV-1) infected subjects who participated in rilpivirine pediatric studies
REFNo: HS1013ES
Primary Endpoint
The primary objective of the study is to provide continued access to RPV, however there is no primary endpoint defined for this study.
Secondary Endpoint
The secondary endpoints are applicable for all subjects until data collection is terminated, as indicated.
Major Secondary Endpoints
The proportion of subjects experiencing adverse events (AEs) considered to be at least possibly related to RPV, AEs leading to discontinuation, serious adverse events (SAEs), pregnancies, and grade 3/4 rash regardless of causality throughout the study. Results of routine safety laboratory tests will only be collected if related to these types of AEs.
Other Secondary Endpoint
The proportion of subjects maintaining viral suppression (ie, <50 HIV-1 RNA copies/mL) based on available viral load data throughout the study. In case of virologic failure, emergence of resistance will also be evaluated based on available genotype/phenotype data.
|
Uganda |
2021-02-05 |
2024-02-05 |
Medical and Health Sciences |
|
Non-degree Award |
|
Jennifer Serwanga
ID: UNCST-2024-R002056
|
Preparation of an Inactivated covid-19 vaccine at UVRI for pre-clinical evaluations at COVAB and an Outsourced primate centre
REFNo: HS1018ES
Collect nasopharyngeal swab of circulating virus strains
b. Isolate local and globally representative wildtype SARS-CoV2 stocks
c. Generate inactivated SARS-CoV-2 products (The Vaccine).
d. Generate SARS-CoV-2 and other b-CoVs pseudovirus stocks
e. Develop assays to distinguish SARS-CoV-2 binding antibodies
f. Develop assays to distinguish SARS-CoV-2 functional neutralizing antibodies
g. Assess inactivated vaccine in Humanized ACE2 mice challenge models
h. Challenge Macaque models to assess safety, immunogenicity and protectiveness
i. Assess immunized mice for vaccine-induced antibody responses
j. Assess immunized mice for vaccine induced cellular responses
k. Assess immunized mice plasma for inflammatory responses
l. Immuno/histopathology of immunized mice organs/tissues
m. Train and develop capacity for skill transfer
The research questions are;
• Will the inactivated vaccine protect challenged mice against developing COVID-19
disease?
• Will the vaccine elicit potent neutralizing antibodies against diverse SARS-CoV-2
strains and how potent are these antibodies?
• Will the vaccine protect the challenged mice against severe inflammatory responses
and organ pathology?
• Will the inactivated vaccine elicit potent and protective effector T -Cell responses?
|
Uganda |
2021-02-05 |
2024-02-05 |
Medical and Health Sciences |
|
Non-degree Award |
|
| View |
|
Sort By: |
|
|
|
| |
|